Jason Barton, DO
Family Medicine · Parkersburg, WVNPI 1407859218
Payments from drug & device makers
Across 332 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$659
- Pfizer$656
- AstraZeneca$465
- Corcept Therapeutics$307
- Amgen$274
- plus $1K from 19 others
What the payments were for
- Food & beverage$5,267100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 103 | $1,449 |
| Novo Nordisk | 46 | $659 |
| Pfizer | 49 | $656 |
| AstraZeneca | 23 | $465 |
| Corcept Therapeutics | 15 | $307 |
| Amgen | 18 | $274 |
| Lilly USA, LLC | 15 | $235 |
| Bayer | 9 | $232 |
| Astellas Pharma US Inc | 11 | $177 |
| GSK | 7 | $144 |
| Exact Sciences | 5 | $91 |
| Boehringer Ingelheim | 6 | $90 |
| Nestle Healthcare Nutrition Inc. | 2 | $82 |
| Novartis | 4 | $72 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $56 |
| Sumitomo Pharma America, Inc. | 2 | $41 |
| Idorsia Pharmaceuticals US Inc | 2 | $37 |
| Merck | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Dexcom, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| MDD US Operations, LLC | 1 | $13 |
How this compares
$5,275 in reported general payments places this provider in the 90th percentile of 843 family medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 233 | $234,998 |
| EliquisApixaban | 193 | $179,941 |
| MounjaroTirzepatide | 101 | $138,801 |
| FarxigaDapagliflozin Propanediol | 95 | $97,637 |
| OzempicSemaglutide | 68 | $90,714 |
| TrulicityDulaglutide | 55 | $80,275 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $66,132 |
| XareltoRivaroxaban | 43 | $45,451 |
| TradjentaLinagliptin | 50 | $45,266 |
| RybelsusSemaglutide | 35 | $43,690 |
| LinzessLinaclotide | 44 | $39,640 |
| VascepaIcosapent Ethyl | 75 | $39,519 |
| MyrbetriqMirabegron | 47 | $32,800 |
| JanuviaSitagliptin Phosphate | 30 | $30,278 |
| EntrestoSacubitril/Valsartan | 31 | $26,251 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $90 | $280,264283 claims |
| Lilly USA, LLCMounjaro, Trulicity | $235 | $219,076156 claims |
| PfizerEliquis | $656 | $179,941193 claims |
| Novo NordiskOzempic, Rybelsus | $659 | $134,405103 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $465 | $132,300178 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $144 | $91,783109 claims |
| AbbVieLinzess, Creon | $1,449 | $64,53072 claims |
| MerckJanuvia, Belsomra | $33 | $41,52754 claims |
| Astellas Pharma US IncMyrbetriq | $177 | $32,80047 claims |
| NovartisEntresto | $72 | $26,25131 claims |
| BayerKerendia | $232 | $7,77912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 843 family medicine providers in West Virginia.
Other family medicine in Parkersburg
- James SpychalskiParkersburg$16K
- Wilbur SineMorgantown$179K
- Dorian WilliamsMorgantown$169K
- Julie DetempleSouth Charleston$129K
- Clemente DiazRichwood$127K
- John CornellHuntington$94K
- Mark CucuzzellaHarpers Ferry$59K
- Courtney PilkertonMorgantown$45K
- Isha WoofterClarksburg$27K
- Dominick WoofterClarksburg$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.